RICHMOND, VA – October 17, 2025: BrainBox Solutions has published a major analysis in JAMA Network OPEN from its HeadSMART II trial, evaluating over 1,000 patients with suspected mild traumatic brain injury (mTBI). The study demonstrates the potential of BrainBox TBI, a multi-modal diagnostic test combining clinical data, neurocognitive testing, symptom reporting, blood-based biomarkers, and AI algorithms, to predict persistent post-concussive symptoms.
Science Significance
This analysis identifies early patient characteristics that correlate with persistent symptoms at 30 days, marking the first large-scale study to quantify risk factors for prolonged mTBI outcomes. The data provide a foundation for objective, AI-driven concussion diagnostics that may transform emergency care and neurotrauma research.
Regulatory Significance
BrainBox TBI has received FDA Breakthrough Device Designation, and the trial design was developed in collaboration with the FDA. This highlights the regulatory confidence in the device and its potential to establish a new standard of care in mTBI diagnosis and prognosis.
Business Significance
Advertisement
With over 5.2 million annual U.S. ED visits for suspected traumatic brain injuries, BrainBox Solutions is positioned to capture significant market share in neurotrauma diagnostics. The company’s IP portfolio now includes 24 patents, further strengthening its commercial prospects and collaborations, including a recent partnership with Oragenics to integrate diagnostics with emerging therapeutics.
Patients’ Significance
The study demonstrates that early identification of patients at risk for persistent symptoms can lead to timely interventions, improving recovery trajectories. The tool’s AI-assisted multi-marker assessment enables clinicians to triage patients more effectively and monitor treatment responses, particularly benefiting elderly and high-risk populations.
Policy Significance
These findings could influence clinical guidelines for ED mTBI evaluation, supporting policies that prioritize objective, data-driven approaches over symptom-only assessments. By defining patient subgroups at risk for long-term outcomes, BrainBox TBI could also shape reimbursement and healthcare resource allocation policies.
The HeadSMART II trial sets a new benchmark in concussion diagnostics, combining AI, biomarkers, and clinical evaluation. With ongoing 90-day follow-ups and future regulatory milestones, BrainBox Solutions is driving the evolution of personalized, data-driven care for mild traumatic brain injury, reinforcing its leadership in MedTech innovation.
Source: BRAINBox Solutions, Inc. press release
